Trevi Therapeutics Financial Ratios
NASDAQ: TRVIHealth CareBiotechnology: Pharmaceutical PreparationsUSD
13.19+0.365 (+2.85%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Trevi Therapeutics ratio analysis
Return on equity reached -23.3%, meaning Trevi Therapeutics generated -0.23 dollars of profit for every dollar of shareholders' equity. Valuation ratios use the closing share price on each fiscal year-end date and diluted shares from the income statement; profitability and leverage ratios use reported annual figures. Current valuation multiples are on the statistics page.
Summary generated from market data by MetaCap's automated system. Methodology
Trevi Therapeutics financial ratios (annual)
| Ratio | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Price / book | 8.74 | 4.70 | 1.61 | 1.16 | 1.05 | 1.60 | 0.92 | — |
| Return on equity (ROE) | -23.3% | -48.1% | -35.2% | -27.1% | -198.8% | -120.1% | -47.8% | — |
| Return on assets (ROA) | -22.1% | -43.2% | -32.5% | -23.7% | -88.2% | -69.5% | -43.4% | -195.2% |
| Current ratio | 19.66 | 10.41 | 15.03 | 9.15 | 2.98 | 8.33 | 11.45 | 3.30 |